Welcome to our dedicated page for Definitive Healthcare news (Ticker: DH), a resource for investors and traders seeking the latest updates and insights on Definitive Healthcare stock.
Definitive Healthcare Corp (DH) provides actionable healthcare commercial data through its SaaS platform, empowering strategic decisions across the $4 trillion U.S. healthcare sector. This news hub delivers verified updates about DH's operational developments, financial milestones, and market leadership.
Key resources include: Earnings call summaries, product enhancement announcements, executive leadership changes, and partnership disclosures. Investors gain insights into recurring revenue trends while healthcare professionals track innovations in provider analytics and predictive modeling tools.
All content undergoes strict editorial review using primary sources including SEC filings and official company communications. Bookmark this page for real-time updates on DH's expanding data ecosystem covering 2.7M+ healthcare providers and 10K+ technology installations.
Definitive Healthcare (Nasdaq: DH) announced inducement awards for two newly hired senior leaders. The company granted 172,414 time-based restricted stock units (RSUs) to Kate Hastings, the new Chief Customer Officer, and 1,018,330 RSUs to Benjamin Graboske, the new EVP, Technology, Engineering and Chief Data Officer, both effective March 3, 2025.
The awards, granted under Nasdaq Listing Rule 5635(c)(4) and Definitive Healthcare's 2023 Inducement Plan, feature a vesting schedule where 25% vests initially (February 1, 2026 for Hastings; April 1, 2026 for Graboske), with the remainder vesting quarterly at 6.25% over three years, subject to continued employment.
Definitive Healthcare (DH) reported mixed Q4 and full-year 2024 results. Q4 revenue declined 6% to $62.3 million, while full-year revenue slightly increased to $252.2 million. The company recorded significant goodwill impairment charges of $97.1 million in Q4 and $688.9 million for the full year.
Q4 highlights include: Net Loss of $(84.7) million, Adjusted Net Income of $12.6 million, and Adjusted EBITDA of $17.5 million (28% margin). Full-year metrics showed improvement in cash flow operations, up 41% to $58.2 million, and Unlevered Free Cash Flow increased 6% to $72.5 million.
The company announced Casey Heller will become CFO effective June 2, 2025. For 2025, DH projects revenue between $230.0-$240.0 million and Adjusted EBITDA of $61.0-$65.0 million with 26-28% margin.
Definitive Healthcare (Nasdaq: DH), a leader in healthcare commercial intelligence, has announced its participation in the upcoming Raymond James 2025 Institutional Investors Conference. CEO Kevin Coop and CFO Rick Booth will deliver a presentation on Tuesday, March 4, 2025, at 3:25 p.m. Eastern Time.
Investors and interested parties can access the live presentation through a webcast available on the Events page of Definitive Healthcare's investor relations website at https://ir.definitivehc.com/. A recorded version of the presentation will be accessible for a time after the event.
Definitive Healthcare (Nasdaq: DH), a healthcare commercial intelligence company, has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, February 27, 2025, after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the results.
Investors can access the live audio webcast through the company's Investor Relations website at ir.definitivehc.com. A dial-in option will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international). A replay will be accessible through March 29, 2025, using 800-645-7964 or 757-849-6722 with passcode 1765#.
Definitive Healthcare (Nasdaq: DH) has been named among Built In's 100 Best Places to Work in Boston for 2025. The recognition, which includes companies of various sizes and both remote-first and traditional employers, highlights DH's commitment to employee satisfaction and workplace culture.
CEO Kevin Coop emphasized the company's focus on making an impact in healthcare and fostering a culture of innovation where employees are empowered to contribute. The selection process by Built In evaluated compensation, benefits, and various workplace attributes including remote work opportunities, DEI programs, and cultural offerings.
The company offers notable benefits including unlimited PTO, hybrid work options, and half-day Summer Fridays for U.S. employees. DH also provides extensive professional development opportunities through continuous learning, leadership development, and educational support programs. This recognition reflects the company's dedication to creating an environment where innovation and individual growth flourish while maintaining work-life balance.
Definitive Healthcare (Nasdaq: DH), a leader in healthcare commercial intelligence, has announced its participation in the 27th Annual Needham Growth Conference. CEO Kevin Coop and CFO Rick Booth will deliver a presentation on Wednesday, January 15, 2025, at 2:15 p.m. Eastern Time.
Definitive Healthcare reported Q3 2024 financial results with revenue of $62.7 million, a 4% decrease from Q3 2023. Net loss was $(187.8) million, including goodwill impairment charges of $228.2 million. Adjusted net income rose to $15.4 million from $14.6 million, while adjusted EBITDA fell 5% to $20.6 million. Cash flow from operations was $19.4 million, and unlevered free cash flow was $24.3 million. The company announced a $100 million stock repurchase program starting in 2025. Customer base grew to 530 enterprise clients. CFO Richard Booth will leave by June 1, 2025. Q4 2024 revenue guidance is $60.0-$61.0 million, adjusted net income $10.5-$11.5 million, and full-year 2024 revenue is expected to be $250.0-$251.0 million.
Definitive Healthcare (Nasdaq: DH) has scheduled its third quarter 2024 financial results announcement for Thursday, November 7, 2024, after market close. The healthcare commercial intelligence company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the results. Investors can access the live audio webcast on the company's IR website and join via phone using domestic (877-358-7298) or international (+1-848-488-9244) dial-in numbers. A replay will be available until December 7, 2024.
Definitive Healthcare (Nasdaq: DH) has launched Monocl Conferences, a solution designed to enhance conference planning and participation for life science organizations. This intuitive platform provides medical affairs, marketing, and conference planning teams with rich, contextualized conference data and access to key experts.
Key features include:
- Visualized conference data dashboard
- Searchable conference insights
- Comparable data for monitoring trends
Monocl Conferences offers quick access to presentations, competitor analysis, social media insights, and details about centers of excellence. It aims to streamline planning, drive strategic engagement, and support organizations in delivering innovative therapies and medical devices to improve patient outcomes.
Definitive Healthcare (Nasdaq: DH) has launched Market Forecast, a predictive analytics solution designed to help healthcare organizations identify high-growth markets and service line opportunities. This new tool provides three, five, and 10-year market trend projections to strengthen strategic planning around future demand and growth opportunities.
Market Forecast aims to empower business development teams, service line leaders, and strategy executives by delivering year-over-year growth rate and market demand projections. This enables healthcare organizations to:
- Drive improved patient acquisition and retention
- Plan market expansion
- Allocate resources more effectively
The solution is particularly valuable for academic medical centers and other healthcare providers looking to identify services with the greatest potential for future growth, even when current volumes may not reflect that opportunity.
FAQ
What is the current stock price of Definitive Healthcare (DH)?
What is the market cap of Definitive Healthcare (DH)?
